Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin Dreesen

Showing results (41-50 of 105) with videos related to

Pageof 11
Sort By:
Antibiotics (Basel, Switzerland)|June 2, 2021
Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort StudyMatthias Gijsen, Erwin Dreesen, Ruth Van Daele, et al.
Journal of Crohn'S & Colitis|September 22, 2018
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Clinical Pharmacokinetics|April 8, 2026
Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's DiseaseWei Zhang, Zhigang Wang, Thierry Dervieux, et al.
Therapeutic Drug Monitoring|January 12, 2019
Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Therapeutic Drug Monitoring|July 14, 2017
Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic ModelingChristophe Passot, Mieke F Pouw, Denis Mulleman, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 12, 2019
Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Infection|December 6, 2024
Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasisOmar Elkayal, Yannick Hoffert, Beatrijs Mertens, et al.
The Journal of Antimicrobial Chemotherapy|July 11, 2022
Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumoniaErwin Dreesen, Matthias Gijsen, Omar Elkayal, et al.
Clinical Pharmacokinetics|October 24, 2024
Correction: Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software ToolsYannick Hoffert, Nada Dia, Tim Vanuytsel, et al.
Therapeutic Drug Monitoring|May 9, 2025
Dose Optimization of Amikacin in the Emergency Department: A Population Pharmacokinetics Simulation StudyNada Dia, Sabrina De Winter, Matthias Gijsen, et al.
Pageof 11

Showing results (41-50 of 105) with videos related to

Sort By:
Pageof 11
Antibiotics (Basel, Switzerland)|June 2, 2021
Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort StudyMatthias Gijsen, Erwin Dreesen, Ruth Van Daele, et al.
Journal of Crohn'S & Colitis|September 22, 2018
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Clinical Pharmacokinetics|April 8, 2026
Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's DiseaseWei Zhang, Zhigang Wang, Thierry Dervieux, et al.
Therapeutic Drug Monitoring|January 12, 2019
Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Therapeutic Drug Monitoring|July 14, 2017
Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic ModelingChristophe Passot, Mieke F Pouw, Denis Mulleman, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 12, 2019
Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel DiseaseKaren van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Infection|December 6, 2024
Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasisOmar Elkayal, Yannick Hoffert, Beatrijs Mertens, et al.
The Journal of Antimicrobial Chemotherapy|July 11, 2022
Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumoniaErwin Dreesen, Matthias Gijsen, Omar Elkayal, et al.
Clinical Pharmacokinetics|October 24, 2024
Correction: Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software ToolsYannick Hoffert, Nada Dia, Tim Vanuytsel, et al.
Therapeutic Drug Monitoring|May 9, 2025
Dose Optimization of Amikacin in the Emergency Department: A Population Pharmacokinetics Simulation StudyNada Dia, Sabrina De Winter, Matthias Gijsen, et al.
Pageof 11